Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Melissa M. Messineo"'
Autor:
Pasi A. Jänne, David M. Jackman, Paul Kirschmeier, Mohit Butaney, Jason J. Luke, Melissa M. Messineo, Allison O'Connell, Stacy L. Mach, Yanan Kuang, Cloud P. Paweletz, Geoffrey R. Oxnard
PDF file - 71K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::745bf69c19c3784a647cbb11f0986d98
https://doi.org/10.1158/1078-0432.22451604.v1
https://doi.org/10.1158/1078-0432.22451604.v1
Autor:
Pasi A. Jänne, David M. Jackman, Paul Kirschmeier, Mohit Butaney, Jason J. Luke, Melissa M. Messineo, Allison O'Connell, Stacy L. Mach, Yanan Kuang, Cloud P. Paweletz, Geoffrey R. Oxnard
XLSX file - 25K, cfDNA results for figures 2, 4, 5, calculated both as concentration per mL plasma and as percent mutant.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06ed8cfb0b1ad3eb3ccc627c7cb9a384
https://doi.org/10.1158/1078-0432.22451607.v1
https://doi.org/10.1158/1078-0432.22451607.v1
Autor:
Pasi A. Jänne, David M. Jackman, Paul Kirschmeier, Mohit Butaney, Jason J. Luke, Melissa M. Messineo, Allison O'Connell, Stacy L. Mach, Yanan Kuang, Cloud P. Paweletz, Geoffrey R. Oxnard
PDF file - 365K, Supplemental Figure 1: Assay optimization. For each TaqMan probe, the optimal annealing temperature was determined by testing each assay across a temperature gradient of 55.0 - 65{degree sign}C. Typical FAM plots for EGFR L858R (A) a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73725199f091d02712e2b455e8d61cda
https://doi.org/10.1158/1078-0432.22451601.v1
https://doi.org/10.1158/1078-0432.22451601.v1
Autor:
Pasi A. Jänne, David M. Jackman, Paul Kirschmeier, Mohit Butaney, Jason J. Luke, Melissa M. Messineo, Allison O'Connell, Stacy L. Mach, Yanan Kuang, Cloud P. Paweletz, Geoffrey R. Oxnard
PDF file - 91K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21338d491f7ad3291fb192f3468b15d8
https://doi.org/10.1158/1078-0432.22451598
https://doi.org/10.1158/1078-0432.22451598
Autor:
Pasi A. Jänne, David M. Jackman, Paul Kirschmeier, Mohit Butaney, Jason J. Luke, Melissa M. Messineo, Allison O'Connell, Stacy L. Mach, Yanan Kuang, Cloud P. Paweletz, Geoffrey R. Oxnard
Purpose: Tumor genotyping using cell-free plasma DNA (cfDNA) has the potential to allow noninvasive assessment of tumor biology, yet many existing assays are cumbersome and vulnerable to false-positive results. We sought to determine whether droplet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdec672afc96338c1972a3bf3040d9b9
https://doi.org/10.1158/1078-0432.c.6522228.v1
https://doi.org/10.1158/1078-0432.c.6522228.v1
Autor:
Stacy L. Mach, David M. Jackman, Pasi A. Jänne, Geoffrey R. Oxnard, Jason J. Luke, Allison O'Connell, Mohit Butaney, Paul Kirschmeier, Yanan Kuang, Melissa M. Messineo, Cloud P. Paweletz
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 20(6)
Purpose: Tumor genotyping using cell-free plasma DNA (cfDNA) has the potential to allow noninvasive assessment of tumor biology, yet many existing assays are cumbersome and vulnerable to false-positive results. We sought to determine whether droplet
Autor:
Mohit Butaney, Melissa M. Messineo, Cam Anh Tran, Amanda J. Redig, Allison O'Connell, Antonio Calles, Sangeetha Palakurthi, Cloud P. Paweletz, Pasi A. Jänne, Shruti D. Shah, Jihyun Choi, Mosab Ali, Yanan Kuang, Masahiko Yanagita, Paul Kirschmeier, Prafulla C. Gokhale, Man Xu, Atsuko Ogino
Publikováno v:
Cancer Research. 75:1451-1451
Background: Genotype directed treatment is the standard of care for patients with advanced non-small cell lung cancer (NSCLC). However, acquired drug resistance invariably develops. There is a need to develop clinically relevant animal models from pa
Autor:
Jessie M. English, Pasi A. Jänne, Yanan Kuang, Allison O'Connell, Masahiko Yanagita, Cloud P. Paweletz, Geoffrey R. Oxnard, Melissa M. Messineo, Paul Kirschmeier, David M. Jackman
Publikováno v:
Cancer Research. 74:939-939
Tumor genotyping has become standard in the care of non-small cell lung cancer (NSCLC), colorectal cancer, and melanoma because of its power in guiding the personalization of treatment with molecularly targeted therapies. A major limitation of cancer